DengYueMed is a China-focused pharmaceutical export wholesaler headquartered in Hong Kong. We offer more than 30,000 types of medicines, covering Chinese innovative drugs, oncology, hematology, orphan drugs, and a wide range of hospital-needed pharmaceuticals. Through our extensive international trade network, we are committed to ensuring the global supply of high-quality medicines to meet the healthcare needs of different regions. We consistently prioritize drug safety, efficacy, and stable quality, ensuring that all our products comply with international certification standards.
-
5 Publicações
-
2 fotos
-
0 Vídeos
-
Outro
-
08/09/2005
-
Seguido por 1 pessoas
Atualizações recentes
-
China's Innovative Drug Export: Accelerating a New Era of GlobalizationIn the pharmaceutical landscape of 2025, Chinese innovative drug companies are advancing onto the international stage at an unprecedented pace. Over the past 24 hours, several key developments have highlighted this trend, showcasing not only the innovative prowess of Chinese firms but also the deepening of global collaborations. According to the latest drug price registration system launched by...0 Comentários 0 Compartilhamentos 14 Visualizações 0 AnteriorFaça o login para curtir, compartilhar e comentar!
-
0 Comentários 0 Compartilhamentos 10 Visualizações 0 Anterior
-
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List PriceIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...0 Comentários 0 Compartilhamentos 1KB Visualizações 0 Anterior
-
PARSABIV (Etelcalcetide Hydrochloride Injection) – Mechanism of Action and DosageBelow is a detailed description of the mechanism of action and dosage of PARSABIV (Etelcalcetide Hydrochloride Injection): Mechanism of Action PARSABIV is a synthetic calcimimetic peptide drug. Its active ingredient, etelcalcetide, specifically binds to and activates the calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the physiological effects of increased...0 Comentários 0 Compartilhamentos 1KB Visualizações 0 Anterior
-
0 Comentários 0 Compartilhamentos 385 Visualizações 0 Anterior
Mais stories